This tender seeks a provider for an Early Infant Diagnosis Screening Assay for HIV nucleic acid qualitative detection, including service and maintenance for three years. Bidders must demonstrate compliance with technical specifications and provide comprehensive support.
The National Health Laboratory Service (NHLS) invites bids for the placement of an Early Infant Diagnosis Screening Assay focused on HIV nucleic acid qualitative detection. This tender encompasses not only the supply of the assay but also includes a robust service and maintenance agreement for a period of three years. The successful bidder will be responsible for ensuring the assay meets the stringent requirements for detecting low levels of HIV in infants, particularly in the context of maternal antiretroviral therapy and infant prophylaxis. Bidders must provide detailed technical specifications, including sensitivity and specificity metrics, as well as a comprehensive support plan that includes training for laboratory personnel.
The NHLS operates a critical Early Infant Diagnosis program, performing over 516,000 tests annually across multiple laboratories. This tender aims to enhance the existing testing capabilities by integrating advanced molecular testing solutions that facilitate timely diagnosis and treatment initiation for infants. The selected provider will contribute to the NHLS's mission of reducing pediatric morbidity and mortality associated with HIV through reliable and efficient testing services. Bidders are required to demonstrate their capacity to deliver high-quality products and services, including compliance with all regulatory standards and the provision of necessary training and support to laboratory staff.
This tender is suitable for businesses specializing in medical diagnostics, particularly those with experience in HIV testing technologies and laboratory support services. Companies that can provide comprehensive training and maintenance solutions for diagnostic equipment are encouraged to apply.